In today’s recent session, 0.53 million shares of the Atara Biotherapeutics Inc (NASDAQ:ATRA) have been traded, and its beta is 0.47. Most recently the company’s share price was $5.74, and it changed around -$0.83 or -12.61% from the last close, which brings the market valuation of the company to $33.07M. ATRA at last check was trading at a discount to its 52-week high of $39.50, offering almost -588.15% off that amount. The share price’s 52-week low was $6.50, which indicates that the recent value has fallen by an impressive -13.24% since then. We note from Atara Biotherapeutics Inc’s average daily trading volume that its 10-day average is 0.51 million shares, with the 3-month average coming to 172.46K.
Atara Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended ATRA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight.
Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information
Instantly ATRA has been showing red trend so far today with a performance of -12.61% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 17.23 on recent trading dayincreased the stock’s daily price by 66.69%. The company’s shares are currently down -56.86% year-to-date, but still down -64.54% over the last five days. On the other hand, Atara Biotherapeutics Inc (NASDAQ:ATRA) is -44.53% down in the 30-day period. We can see from the shorts that 0.64 million shares have been sold at a short interest cover period of 7.11 day(s).
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 59.0% from its current value. Analyst projections state that ATRA is forecast to be at a low of $10 and a high of $18.
Atara Biotherapeutics Inc (ATRA) estimates and forecasts
Atara Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -47.85 percent over the past six months and at a 84.89% annual growth rate that is well above the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 13.12%.
ATRA Dividends
Atara Biotherapeutics Inc’s next quarterly earnings report is expected to be released in February.
Atara Biotherapeutics Inc (NASDAQ:ATRA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 22.15% of Atara Biotherapeutics Inc shares, and 50.82% of them are in the hands of institutional investors. The stock currently has a share float of 65.29%. Atara Biotherapeutics Inc stock is held by 67.0 institutions, with BOXER CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 0.1181% of the shares, which is about 0.17 million shares worth $1.41 million.
LAKE STREET ADVISORS GROUP, LLC, with 0.0078% or 11000.0 shares worth $93500.0 as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 120.26 shares worth $0.75 million, making up 2.09% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 54.47 shares worth around $0.34 million, which represents about 0.95% of the total shares outstanding.
